Ignacio
Melero
Catedrático de Universidad
Publications (382) Ignacio Melero publications
2024
-
CD137 (4-1BB) and T-Lymphocyte Exhaustion
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 18, pp. 3971-3973
-
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials
Nature Communications, Vol. 15, Núm. 1
-
Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross-priming
Immunological Reviews, Vol. 321, Núm. 1, pp. 143-151
-
Double-Stranded RNA to Mimic Viral Infection for Cancer Immunotherapy
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 16, pp. 3355-3357
-
Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 4
-
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 3
-
Intratumoral NK cell delivery combined with neutralization of the NKG2A pathway as treatment for solid cancer
Genes and Immunity
-
Low-Dose Ionizing γ-Radiation Elicits the Extrusion of Neutrophil Extracellular Traps
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 18, pp. 4131-4142
-
MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers
Journal for immunotherapy of cancer, Vol. 12, Núm. 9
-
Multiplex spatial analysis reveals increased CD137 expression and m-MDSC neighboring tumor cells in refractory classical Hodgkin Lymphoma
OncoImmunology, Vol. 13, Núm. 1
-
Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040
Annals of Oncology, Vol. 35, Núm. 4, pp. 381-391
-
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040
Annals of Oncology, Vol. 35, Núm. 6, pp. 537-548
-
Obinutuzumab Pretreatment as a Novel Approach to Mitigate Formation of Anti-Drug Antibodies Against Cergutuzumab Amunaleukin in Patients with Solid Tumors
Clinical Cancer Research, Vol. 30, Núm. 8, pp. 1630-1641
-
Regional and intratumoral adoptive T-cell therapy
Immuno-Oncology and Technology, Vol. 24
-
Reply to the Letter to the Editor “Reflections on the statistical methodology in nivolumab and ipilimumab therapy research” by S. Yang
Annals of Oncology
-
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors
Clinical Cancer Research, Vol. 30, Núm. 13, pp. 2693-2701
-
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial
Nature Communications, Vol. 15, Núm. 1
-
Short-term cultured tumor fragments to study immunotherapy combinations based on CD137 (4-1BB) agonism
OncoImmunology, Vol. 13, Núm. 1
-
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease
Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 4
-
Spatially resolved tissue imaging to analyze the tumor immune microenvironment: beyond cell-type densities
Journal for immunotherapy of cancer, Vol. 12, Núm. 5